Is Zentalis Pharmaceuticals, Inc. overvalued?

Zentalis Pharmaceuticals, Inc. (ZNTL) — key valuation metrics and fundamentals.

No verdict

Price

$1.70

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$167.1M

Dividend yield

0.0%

Return on equity

-75.8%

Sector

Healthcare

Fair value compares ZNTL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks